Each year about half of Canada’s seven million children use at least one prescription drug, but much of the time, the prescription is "off label" or differs from an authorized use, which creates potential health risks.
Health Canada asked an expert panel to analyze the gaps, opportunities and challenges of prescription drug use in children. On Thursday, the Council of Canadian Academies’ expert panel released its report.
"It's clearly unacceptable to go on treating 20 or 30 per cent of the population with therapies that have not been validated in a scientific fashion that's been required for 50 years in the adult world," said Dr. Stuart MacLeod, a pediatrics professor at the University of British Columbia, who led the expert panel.
Children should be protected through research, not protected from it, he said.
The panel’s findings include:- Children take many medications that have not been proven safe and effective for their use.
- Children respond to medications differently from adults and may need liquids instead of pills. When that's not available, adapting existing forms of medication based on evidence-based standards would make them safer.
- Health Canada can’t compel drug manufacturers to study their products in children and youth, while in the U.S. and the European Union, pediatric medicine research is encouraged, required and monitored.
- Strong adverse drug reaction databases are needed with more active surveillance.
The U.S. and Europe have done studies in children for years to determine the safety, effectiveness and proper dosages, said Dr. Anne Junker of BC Children’s Hospital and scientific director of the Canadian Child & Youth Health Coalition.
Junker called it unacceptable that only 14 per cent of clinical trials are specifically designed for use in children.
Junker and MacLeod said Canada has the expertise and a network of children's hospitals that could conduct more pediatric research if the government updates regulations.Suggest a correction